Thursday, 15 October 2026European Markets

ESSILORLUXOTTICA And VIRBAC Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - essilorluxottica (el.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
essilorluxottica (el.pa) €209.70 1.97% 6.3%
virbac (virp.pa) €346.00 0.39% 13.84%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. essilorluxottica (el.pa)

1.97% forward dividend yield and 6.3% return on equity

essilorluxottica société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in europe, the middle east, africa, latin america, the asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the essilor, varilux, crizal, eyezen, stellest, xperio, transitions, ray-ban, oakley, barberini, kodak lens, nikon, shamir, eyexpert, iwear, humanware, and optifog brands. it also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the essilor instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the satisloh brand. in addition, the company provides eyewear products under the ray-ban, oakley, persol, oliver peoples, vogue eyewear, arnette, alain mikli, costa, bliz, native, luxottica, sferoflex, bolon, molsion, dbyd, and unofficial and seen, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.

earnings per share

as for profitability, essilorluxottica has a trailing twelve months eps of €5.08.

pe ratio

essilorluxottica has a trailing twelve months price to earnings ratio of 41.28. meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.3%.

moving average

essilorluxottica's value is higher than its 50-day moving average of €203.27 and way higher than its 200-day moving average of €184.79.

revenue growth

year-on-year quarterly revenue growth grew by 0.4%, now sitting on 25.39b for the twelve trailing months.

volume

today's last reported volume for essilorluxottica is 403928 which is 3.02% above its average volume of 392065.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 6, 2024, the estimated forward annual dividend rate is 3.95 and the estimated forward annual dividend yield is 1.97%.

more news about essilorluxottica.

2. virbac (virp.pa)

0.39% forward dividend yield and 13.84% return on equity

virbac sa manufactures and sells a range of products and services for companion animals and farm animals in france, europe, latin america, north america, asia, pacific, and africa and the middle east. the company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. it serves veterinarians, farmers, and pet owners. virbac sa was founded in 1968 and is headquartered in carros, france.

earnings per share

as for profitability, virbac has a trailing twelve months eps of €14.12.

pe ratio

virbac has a trailing twelve months price to earnings ratio of 24.5. meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.84%.

revenue growth

year-on-year quarterly revenue growth grew by 6.1%, now sitting on 1.25b for the twelve trailing months.

volatility

virbac's last week, last month's, and last quarter's current intraday variation average was a negative 1.36%, a negative 0.24%, and a positive 1.58%.

virbac's highest amplitude of average volatility was 1.36% (last week), 1.50% (last month), and 1.58% (last quarter).

dividend yield

according to morningstar, inc., the next dividend payment is on jun 25, 2024, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.39%.

volume

today's last reported volume for virbac is 11037 which is 150.72% above its average volume of 4402.

more news about virbac.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com